APOLLO: Optimizing the Treatment of High-Risk Acute Promyelocytic Leukemia With All-Trans Retinoic Acid and Arsenic Trioxide While Minimizing the Role of Chemotherapy
Mené sur 133 patients atteints d'une leucémie promyélocytaire aiguë à haut risque de récidive (durée médiane de suivi : 37 mois), cet essai de phase III évalue l'efficacité, du point de vue de la survie sans événement à 2 ans, et la toxicité d'un traitement combinant trioxyde d'arsenic et acide tout-trans rétinoïque
It is almost 70 years since the recognition of acute promyelocytic leukemia (APL) as a unique subtype of AML characterized by a preponderance of promyelocytes, a profound hemorrhagic diathesis because of hyperfibrinolysis and severe thrombocytopenia and a rapidly fatal course.1 That distinction was subsequently validated by identification of the t(15;17) reciprocal translocation with rearrangement of the PML and RARA genes and formation of a PML::RAR
α fusion protein, characteristics which formally define the entity now known as APL with PML::RARA fusion.2 The consequences of this genetic lesion, including nuclear body (NB) disruption, deregulation of stem cell self-renewal, and blockade of myeloid differentiation underpin the basis for the unique sensitivity of APL to treatment with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO).
Journal of Clinical Oncology , éditorial, 2025